| Bioactivity | SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders[1][2]. | ||||||||||||
| Target | IC50: 160 nM (Rev-Erbβ); 170 nM (Rev-Erbα) | ||||||||||||
| Invitro | SR10067 has high affinity for Rev-Erbβ and Rev-Erbαwith IC50 values are 160 and 170 nM, respectively[1]. | ||||||||||||
| In Vivo | SR10067 (i.p.; 30 mg/kg) has good pharmacokinetic properties in mouse[1]. Animal Model: | ||||||||||||
| Name | SR10067 | ||||||||||||
| CAS | 1380548-02-6 | ||||||||||||
| Formula | C31H31NO3 | ||||||||||||
| Molar Mass | 465.58 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Banerjee S, et al. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nat Commun. 2014 Dec 23;5:5759. doi: 10.1038/ncomms6759. [2]. Thevis M, et al. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. Rapid Commun Mass Spectrom. 2016 Mar 15;30(5):635-51. |